In 1940, 12 years after Alexander Fleming discovered penicillin, microbiologists made a concerning discovery: a strain of the bacteria Escherichia coli had developed resistance to the new, life-saving drug. Antibiotic resistance of disease-causing bacteria is now a global problem, with bacteria continually evolving mechanisms that prevent such drugs from killing the organisms or inhibiting their growth. Now Vanderlei Bagnato of the University of São Paulo and his colleagues have developed a light-based approach that could help reduce this trend in a Staphylococcus bacterium that can cause skin infections and pneumonia [1]. The researchers presented their technique at the recent SPIE Photonics West 2024 conference in San Francisco.

If the current trend continues, epidemiologists predict that the number of people infected by antibiotic-resistant bacteria will reach 225 million worldwide by 2030. By 2050 these bacteria will cause 10 million deaths annually. Studies show that infections acquired in hospital are increasingly prone to this problem. “People are dying every day in [intensive care wards] from resistant bacteria. If someone acquires pneumonia, and antibiotics don’t work, they’re in trouble,” Bagnato says.

One route to tackling antibiotic resistance is to develop new drugs, which is a costly process. Another route—and one that is becoming increasingly popular—is to inhibit antibiotic-eluding mechanisms that a bacterium develops as it evolves. This inhibition can be achieved using light, a process those in the field call photodynamics, and the route Bagnato and his colleagues have taken. “We’re using photodynamics to reverse resistance so that antibiotics can act again,” he says.

Researchers from the University of Illinois Chicago and Harvard University have created an antibiotic that may provide medicine a new tool to combat bacteria resistant to drugs and the illnesses they trigger.

The antibiotic, cresomycin, described in Science, effectively suppresses pathogenic bacteria that have become resistant to many commonly prescribed antimicrobial drugs.

The promising novel antibiotic is the latest finding for a longtime research partnership between the group of Yury Polikanov, associate professor of biological sciences at UIC, and colleagues at Harvard. The UIC scientists provide critical insights into cellular mechanisms and structure that help the researchers at Harvard design and synthesize new drugs.

A system that edits RNA rather than DNA can give new life to exhausted CAR T cells.

About a decade ago, researchers in UC Santa Barbara chemistry professor Guillermo Bazan’s lab began to observe a recurring challenge in their research: Some of the compounds they were developing to harness energy from bacteria were instead killing the microbes. Not good if the objective of the project was to harness the metabolism of living bacteria to produce electricity.

“We needed the bacteria to be alive,” said Alex Moreland, a Cystic Fibrosis Foundation Postdoctoral Fellow who joined the Bazan research group as a graduate student in 2014, and currently works at UCSB’s Center for Polymers and Organic Solids. “While we were developing new molecules for that application, we found that some of them didn’t work because they were killing the bacteria.”

However, instead of brushing it off as a rather annoying laboratory curiosity, in subsequent research the team leaned into the apparent antimicrobial properties of these compounds, called conjugated oligoelectrolytes (COE). Fast-forward to today, and they now have the basis for a new class of antibiotics, one that not only shows promise against a broad array of bacterial infections but can also evade the dreaded resistance that has been rendering our current generation of first-line antibiotics ineffective.